12-8　ⓔ文献

  1. Tanaka A, Mori M, et al: Increase trend in the prevalence and male–to–female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res, 2019; 49: 881–889.

  2. Yagi M, Tanaka A, et al: Symptoms and health–related quality of life in Japanese patients with primary biliary cholangitis. Sci Rep, 2018; 8: 12542.

  3. Harada K, Hsu M, et al: Application and validation of a new histologic staging and grading system for primary biliary cirrhosis. J Clin Gastroenterol, 2013; 47: 174–181.

  4. Working Subgroup for Clinical Practice Guidelines for Primary Biliary C, Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res, 2014; 44 Suppl S1: 71–90.

  5. Harada K, Nakanuma Y: Prevalence and risk factors of hepatocellular carcinoma in Japanese patients with primary biliary cirrhosis. Hepatol Res, 2014; 44: 133–140.

  6. Harms MH, van Buuren HR, et al: Ursodeoxycholic acid therapy and liver transplant–free survival in patients with primary biliary cholangitis. J Hepatol, 2019; 71: 357–365.

  7. Tanaka A, Hirohara J, et al: Association of bezafibrate with transplant–free survival in patients with primary biliary cholangitis. J Hepatol, 2021; 75: 565–571.

  8. 猪股裕紀洋，梅下浩司，他：肝移植症例登録報告．移植，2016; 51: 145–159.

  9. Montano–Loza AJ, Hansen BE, et al: Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival. Gastroenterology, 2019; 156: 96–107. e1.

  10. Yagi M, Tanaka A, et al: Is patient–reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post–marketing, single–arm, prospective study. J Gastroenterol, 2018; 53: 1151–1158.